DJ WANG

Dr. DJ WANG

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
BZBitian Zhang
Bitian Zhang
PLPing-Chung Leung
Ping-Chung Leung
William C. ChoWilliam C. Cho
William C. Cho
CWChun-Kwok Wong
Chun-Kwok Wong
DWDJ WANG
DJ WANG
Lung cancer remains the leading cause of cancer-related mortality globally, necessitating the continual exploration of novel therapeutic targets. The phosphoinositide 3-kinase (PI3K) signaling pathway plays a pivotal role in oncogenic processes, including cell growth, survival, metabolism and immune modulation. This comprehensive review delineates the distinct roles of PI3K subtypes—PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ—in lung cancer pathogenesis and progression. We evaluate the current landscape of PI3K inhibitors, transitioning from non-selective early-generation compounds to isoform-specific agents, highlighting their clinical efficacy, resistance mechanisms and potential combination strategies. Furthermore, the intricate interplay between PI3K signaling and the tumor immune microenvironment is explored, elucidating how PI3K modulation can enhance immunotherapeutic responses. Metabolic reprogramming driven by PI3K signaling is also dissected, revealing vulnerabilities that can be therapeutically exploited. Despite promising advancements, challenges such as therapeutic resistance and adverse effects underscore the need for personalized medicine approaches and the development of next-generation inhibitors. This review underscores the multifaceted role of PI3K in lung cancer and advocates for integrated strategies to harness its full therapeutic potential, paving the way for improved patient outcomes.

Verified
Journal Article
Open access
PDF file
BZBitian Zhang
Bitian Zhang
PLPing-Chung Leung
Ping-Chung Leung
CWChun-Kwok Wong
Chun-Kwok Wong
DWDJ WANG
DJ WANG
Glioma is a highly invasive brain cancer that is difficult to treat due to its complex molecular characteristics and poor prognosis. The COVID-19 pandemic has introduced additional clinical challenges for cancer patients, especially those with glioma. This study explored the molecular interactions between glioma and COVID-19 using integrated bioinformatics methods, including enrichment analysis, survival analysis, and molecular docking, focusing on the PI3K-Akt signaling pathway and the immunomodulatory role of vitamin D. From gene expression data of glioma and COVID-19, 203 common differentially expressed genes were identified, and six prognostic key genes—MYBL2, RBM6, VEPH1, AHNAK2, GNG10, and DUSP14—were further determined. After intersecting with vitamin D targets five prognostic key genes were determined—MYBL2, RBM6, VEPH1, AHNAK2 and GNG10. These genes play significant roles in the PI3K-Akt pathway and potentially interact with vitamin D. Molecular docking and single-cell RNA sequencing analyses suggest that vitamin D may improve the prognosis of glioma patients infected with COVID-19 by regulating these key genes and the PI3K-Akt pathway. The findings reveal molecular links between glioma and COVID-19, thereby providing new insights for developing targeted therapeutic strategies.

Verified
Journal Article
Open access
PDF file
DWDJ WANG
DJ WANG
BCBen C. L. Chan
Ben C. L. Chan
BZBitian Zhang
Bitian Zhang
KWKatie Ching-Yau Wong
Katie Ching-Yau Wong
LKLea Ling Yu Kan
Lea Ling Yu Kan
CWChun-Kwok Wong
Chun-Kwok Wong
Environmental pollutants are closely linked to lung cancer. The different types of environmental pollutants can be classified as chemical, physical, and biological. The roles of common chemical and physical pollutants such as PM2.5, smoking, radon, asbestos, and formaldehyde in lung cancer have been extensively studied. Notably, the worldwide COVID-19 pandemic raised awareness of the strong link between biological pollution and human health. Allergens such as house dust mites and pollen, as well as bacteria and viruses, are common biological pollutants. A few biological pollutants have been reported to promote lung cancer via inducing inflammatory cytokines secretion, such as IL-1β, IL-6, and TGF-β, as well as suppressing immunosurveillance by upregulating regulatory T (Treg) cells while dampening the function of CD8+ T cells and dendritic cells. However, the correlation between common biological hazards, such as SARS-CoV-2, human immunodeficiency viruses, Helicobacter pylori, and house dust mites, and lung cancer is not fully elucidated, and the underlying mechanisms are still unclear. Moreover, the majority of studies that have been performed in lung cancer and biological carcinogens were not based on the perspective of biological pollutants, which has challenged the systematicity and coherence in the field of biological pollutants in lung cancer. Here, in addition to reviewing the recent progress made in investigating the roles of allergens, viruses, and bacteria in lung cancer, we summarized the potential mechanisms underlying biological pollutants in lung cancer. Our narrative review can shed light on understanding the significance of biological pollutants in lung cancer, as well as inspire and broaden research ideas on lung cancer etiology.

2 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
BZBitian Zhang
Bitian Zhang
William C. ChoWilliam C. Cho
William C. Cho
PLPing-Chung Leung
Ping-Chung Leung
CWChun-Kwok Wong
Chun-Kwok Wong
DWDJ WANG
DJ WANG
Background: The membrane-spanning 4-domains subfamily A member 2 (MS4A2), a mast cell-specific IgE receptor component, exhibits paradoxical roles in cancer progression. While pan-cancer analyses suggest its context-dependent duality, its prognostic hierarchy across survival metrics – overall survival (OS), disease-specific survival (DSS), progression-free interval (PFI), and disease-free interval (DFI) – remains uncharacterized in lung adenocarcinoma (LUAD). Materials and methods: We integrated bulk RNA-seq (TCGA/GTEx, 33 cancers) and single-cell transcriptomics (NSCLC cohorts) to map MS4A2’s expression dynamics. Prognostic impacts were quantified through Cox regression and Kaplan–Meier modeling for all four survival endpoints (OS/DSS/PFI/DFI), complemented by immune infiltration and methylation-epigenetic correlation analyses. Drug sensitivity associations were evaluated using GDSC pharmacogenomics. Results: Pan-cancer stratification revealed LUAD-specific prognostic dominance of MS4A2, with elevated expression reducing mortality risk (OS HR = 0.58, DSS HR = 0.61; all P < 0.05) and prolonging disease control (PFI HR = 0.59, DFI HR = 0.59; all P < 0.05). Single-cell mapping localized MS4A2 to tumor-associated mast cells, where its bidirectional chemokine regulation – suppressing lymphoid homing (CCL19/CCL21) while amplifying myeloid recruitment (CCL20/CXCL8) – orchestrated leukocyte transendothelial migration. Clinically, MS4A2 exhibited female-biased expression ( P < 0.01) and stage-dependent attenuation ( P < 0.01), correlating with enhanced sensitivity to 5-fluorouracil and axitinib ( P < 0.05) in high-expressing tumors despite their immune-evasive traits. Conclusion: By converging multi-omics evidence across four prognostic axes (OS/DSS/PFI/DFI), we redefine MS4A2 as a mast cell-driven gatekeeper of LUAD progression. Its dual chemokine polarization establishes an immunosuppressive niche paradoxically susceptible to cytotoxic agents, proposing a precision stratification framework: MS4A2 high tumors for 5-FU/axitinib regimens combined with immunotherapies to counterbalance microenvironmental resistance. This quad-metric prognostic model advances LUAD management by linking mast cell biology to clinically actionable survival endpoints.

26 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
BZBitian Zhang
Bitian Zhang
XSXiaoyu Song
Xiaoyu Song
William C. ChoWilliam C. Cho
William C. Cho
CWChun-Kwok Wong
Chun-Kwok Wong
DWDJ WANG
DJ WANG
Objective: Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality, particularly in advanced stages. This study investigates the anticancer mechanisms of calycosin, an isoflavonoid derived from Astragalus membranaceus, in LUAD. Methods: Using integrative approaches including bulk and single-cell RNA sequencing, network pharmacology, and molecular docking, we identified SMAD3 as a critical biomarker associated with LUAD staging and prognosis. Results: Calycosin targets SMAD3, modulating the NOTCH signaling pathway in monocytes/macrophages to suppress tumor growth, invasion, and immune evasion. Enrichment analyses revealed significant involvement of NOTCH signaling components in SMAD3-correlated genes, particularly in advanced-stage LUAD. Single-cell RNA sequencing further demonstrated NOTCH pathway enrichment in tumor-associated monocytes/macrophages. Additionally, KMT2A was identified as a key transcriptional regulator in these cells. Conclusions: These findings highlight the potential effects of calycosin and provide novel insights into targeting the tumor–immune microenvironment in LUAD.

14 June 2025 in Environmental Sciences Europe
Verified
Journal Article
Open access
PDF file
BZBitian Zhang
Bitian Zhang
PLPing-Chung Leung
Ping-Chung Leung
CWChun-Kwok Wong
Chun-Kwok Wong
DWDJ WANG
DJ WANG
Aristolochic acid I (AA-I), a naturally occurring compound derived from plants of the genus Aristolochia, is a well-documented nephrotoxin and carcinogen linked to bladder (BLCA), kidney (KIRC), and liver (LIHC) cancers. Despite extensive research, the molecular mechanisms underlying AA-I-induced carcinogenesis remain incompletely understood. Using in silico multi-omics approaches, we demonstrate that AA-I orchestrates multi-organ carcinogenesis through the rewiring of apoptotic pathways. In BLCA, AA-I modulates apoptotic signaling by targeting key genes, such as ABHD16A, DYRK4, UCHL1, and AHCY, promoting metabolic reprogramming and cell survival. Molecular docking studies reveal direct interactions between AA-I and these proteins, potentially modulating their enzymatic activities. In KIRC, AA-I hijacks apoptotic pathways via mast cells, which emerge as central mediators of immune evasion through ligand–receptor pairs (e.g., MIF–CD74 and CSF1–CSF1R). Mast cells also regulate apoptosis and cell cycle pathways, offering novel therapeutic targets for AA-I-associated renal malignancies. In LIHC, AA-I disrupts apoptotic signaling through oncogenic drivers, such as AGAP9 and WNT8A, while the protective gene SV2C exhibits downregulation in tumors. Our findings highlight the pivotal role of apoptotic pathway dysregulation in AA-I-induced carcinogenesis across multiple cancer types and uncover actionable targets. However, it is important to note that this study is based on the in silico computational analyses, and further experimental validation through in vitro and in vivo studies is necessary to confirm these findings. By elucidating potential targets and mechanisms, this work underscores the need for continued investigation into AA-I's epigenetic impacts and its broader implications for global oncology and public health. Highlights Aristolochic acid I (AA-I) drives tissue-specific oncogenesis through dual mutagenic and non-mutagenic mechanisms Mast cells emerge as key mediators of AA-I-induced immune evasion in kidney cancer AA-I reprograms metabolic and epigenetic networks in bladder cancer Divergent prognostic biomarkers link AA-I exposure to hepatocellular carcinoma outcomes Conserved AA-I interaction networks highlight therapeutic vulnerabilities